Jennifer Catherine Camaradou

Ms. Jennifer Catherine Camaradou

Health, University of Plymouth, Plymouth, UK

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 April 2024 in BMJ
Verified
Journal Article
Open access
PDF file
GCGary S Collins
Gary S Collins
KMKarel G M Moons
Karel G M Moons
PDPaula Dhiman
Paula Dhiman
RRRichard D Riley
Richard D Riley
ABAndrew Beam
Andrew Beam
PLPatricia Logullo
Patricia Logullo
The TRIPOD (Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis) statement was published in 2015 to provide the minimum reporting recommendations for studies developing or evaluating the performance of a prediction model. Methodological advances in the field of prediction have since included the widespread use of artificial intelligence (AI) powered by machine learning methods to develop prediction models. An update to the TRIPOD statement is thus needed. TRIPOD+AI provides harmonised guidance for reporting prediction model studies, irrespective of whether regression modelling or machine learning methods have been used. The new checklist supersedes the TRIPOD 2015 checklist, which should no longer be used. This article describes the development of TRIPOD+AI and presents the expanded 27 item checklist with more detailed explanation of each reporting recommendation, and the TRIPOD+AI for Abstracts checklist. TRIPOD+AI aims to promote the complete, accurate, and transparent reporting of studies that develop a prediction model or evaluate its performance. Complete reporting will facilitate study appraisal, model evaluation, and model implementation.

JCJoht Singh Chandan
Joht Singh Chandan
KBKirsty Rose Brown
Kirsty Rose Brown
NSNikita Simms-Williams
Nikita Simms-Williams
NBNasir Z. Bashir
Nasir Z. Bashir
JCJenny Camaradou
Jenny Camaradou
OAOlalekan Lee Aiyegbusi
Olalekan Lee Aiyegbusi
Background: Post-viral syndromes (PVS), including Long COVID, are symptoms sustained from weeks to years following an acute viral infection. Non-pharmacological treatments for these symptoms are poorly understood. This review summarises the evidence for the effectiveness of non-pharmacological treatments for PVS. Methods: We conducted a systematic review to evaluate the effectiveness of non-pharmacological interventions for PVS, as compared to either standard care, alternative non-pharmacological therapy, or placebo. The outcomes of interest were changes in symptoms, exercise capacity, quality of life (including mental health and wellbeing), and work capability. We searched five databases (Embase, MEDLINE, PsycINFO, CINAHL, MedRxiv) for randomised controlled trials (RCTs) published between 1 January 2001 to 29 October 2021. The relevant outcome data were extracted, the study quality was appraised using the Cochrane risk-of-bias tool, and the findings were synthesised narratively. Findings: Overall, five studies of five different interventions (Pilates, music therapy, telerehabilitation, resistance exercise, neuromodulation) met the inclusion criteria. Aside from music-based intervention, all other selected interventions demonstrated some support in the management of PVS in some patients. Interpretation: In this study, we observed a lack of robust evidence evaluating the non-pharmacological treatments for PVS, including Long COVID. Considering the prevalence of prolonged symptoms following acute viral infections, there is an urgent need for clinical trials evaluating the effectiveness and cost-effectiveness of non-pharmacological treatments for patients with PVS. Registration: The study protocol was registered with PROSPERO [CRD42021282074] in October 2021 and published in BMJ Open in 2022.

27 March 2023 in European Journal of Neurology
Verified
Journal Article
Open access
AFAlessandra Fanciulli
Alessandra Fanciulli
FLFabian Leys
Fabian Leys
MSMagdalena Krbot Skorić
Magdalena Krbot Skorić
DCDiogo Reis Carneiro
Diogo Reis Carneiro
GCGiovanna Calandra‐Buonaura
Giovanna Calandra‐Buonaura
TLThe Collaborators Of European Network Of Neurological Ans Laboratories
The Collaborators Of European Network Of Neurological Ans Laboratories
Background and purpose: The objective was to investigate the impact of the coronavirus disease 2019 (COVID‐19) pandemic on European clinical autonomic practice.Methods: Eighty‐four neurology‐driven or interdisciplinary autonomic centers in 22 European countries were invited to fill in a web‐based survey between September and November 2021.Results: Forty‐six centers completed the survey (55%). During the first pandemic year, the number of performed tilt‐table tests, autonomic outpatient and inpatient visits decreased respectively by 50%, 45% and 53%, and every third center reported major adverse events due to postponed examinations or visits. The most frequent newly diagnosed or worsened cardiovascular autonomic disorders after COVID‐19 infection included postural orthostatic tachycardia syndrome, orthostatic hypotension and recurrent vasovagal syncope, deemed to be likely related to the infection by ≥50% of the responders. Forty‐seven percent of the responders also reported about people with new onset of orthostatic intolerance but negative tilt‐table findings, and 16% about people with psychogenic pseudosyncope after COVID‐19. Most patients were treated non‐pharmacologically and symptomatic recovery at follow‐up was observed in ≥45% of cases. By contrast, low frequencies of newly diagnosed cardiovascular autonomic disorders following COVID‐19 vaccination were reported, most frequently postural orthostatic tachycardia syndrome and recurrent vasovagal syncope, and most of the responders judged a causal association unlikely. Non‐pharmacological measures were the preferred treatment choice, with 50%–100% recovery rates at follow‐up.Conclusions: Cardiovascular autonomic disorders may develop or worsen following a COVID‐19 infection, whilst the association with COVID‐19 vaccines remains controversial. Despite the severe pandemic impact on European clinical autonomic practice, a specialized diagnostic work‐up was pivotal to identify non‐autonomic disorders in people with post‐COVID‐19 orthostatic complaints.

20 September 2022 in European Journal of Neurology
Verified
Journal Article
Open access
Mario HabekMario Habek
Mario Habek
FLFabian Leys
Fabian Leys
MSMagdalena Krbot Skorić
Magdalena Krbot Skorić
DCDiogo Reis Carneiro
Diogo Reis Carneiro
GCGiovanna Calandra‐Buonaura
Giovanna Calandra‐Buonaura
Lucio MarinelliLucio Marinelli
Lucio Marinelli
Background and purpose: Disorders of the autonomic nervous system (ANS) are common conditions, but it is unclear whether access to ANS healthcare provision is homogeneous across European countries. The aim of this study was to identify neurology‐driven or interdisciplinary clinical ANS laboratories in Europe, describe their characteristics and explore regional differences.Methods: We contacted the European national ANS and neurological societies, as well as members of our professional network, to identify clinical ANS laboratories in each country and invite them to answer a web‐based survey.Results: We identified 84 laboratories in 22 countries and 46 (55%) answered the survey. All laboratories perform cardiovascular autonomic function tests, and 83% also perform sweat tests. Testing for catecholamines and autoantibodies are performed in 63% and 56% of laboratories, and epidermal nerve fiber density analysis in 63%. Each laboratory is staffed by a median of two consultants, one resident, one technician and one nurse. The median (interquartile range [IQR]) number of head‐up tilt tests/laboratory/year is 105 (49–251). Reflex syncope and neurogenic orthostatic hypotension are the most frequently diagnosed cardiovascular ANS disorders. Thirty‐five centers (76%) have an ANS outpatient clinic, with a median (IQR) of 200 (100–360) outpatient visits/year; 42 centers (91%) also offer inpatient care (median 20 [IQR 4–110] inpatient stays/year). Forty‐one laboratories (89%) are involved in research activities. We observed a significant difference in the geographical distribution of ANS services among European regions: 11 out of 12 countries from North/West Europe have at least one ANS laboratory versus 11 out of 21 from South/East/Greater Europe (p = 0.021).Conclusions: This survey highlights disparities in the availability of healthcare services for people with ANS disorders across European countries, stressing the need for improved access to specialized care in South, East and Greater Europe.

31 July 2025 in Ewha Medical Journal
Verified
Journal Article
Open access
PDF file
GCGary S Collins
Gary S Collins
KMKarel G M Moons
Karel G M Moons
PDPaula Dhiman
Paula Dhiman
RRRichard D Riley
Richard D Riley
ABAndrew Beam
Andrew Beam
PLPatricia Logullo
Patricia Logullo
TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods: a Korean translation

12 April 2023 in Advances in Therapy
Verified
Journal Article
Open access
PDF file
JCJennifer Catherine Louise Camaradou
Jennifer Catherine Louise Camaradou
HHHenry David Jeffry Hogg
Henry David Jeffry Hogg
Artificial intelligence (AI) in healthcare has now begun to make its contributions to real-world patient care with varying degrees of both public and clinical acceptability around it. The heavy investment from governments, industry and academia needed to reach this point has helped to surface different perspectives on AI. As clinical AI applications become a reality, however, there is an increasing need to harness and integrate patient perspectives, which address the distinct needs of different populations, healthcare systems and clinical problems more closely. Despite this need, patient perspectives on AI implementation have little presence in academic literature and within implementation science and are not sufficiently considered throughout the MedTech and eHealthtech product development cycle, which brings its own challenges and opportunities. This joint patient expert/clinician commentary aims to briefly summarise views on AI. It reflects upon recommendations on how stakeholders such as clinicians and Health & MedTech small and medium-sized enterprises (SMEs) can make practical usage of these views. The recommendations of the authors centre around how to work better with patients to enable both product centric and patient centric innovation and person-centred care.